Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.
We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.
We offer radioisotopes for clinical applications as well as research purposes. We have therefore established a GMP manufacturing of a first-in-class radioisotopes and -generator platform for the development of a new generation of targeted cancer diagnostics and therapies.
In 2016, we received Marketing Authorization for EndolucinBeta®. EndolucinBeta® respectively no-carrier-added (n.c.a.) lutetium (177Lu) chloride is a radiopharmaceutical precursor and indicated for the radiolabeling of disease-specific carrier molecules. The emerging radiopharmaceutical can be applied in Targeted Radionuclide Therapy for cancer treatment.
Get in touch with our Sales Team
If you are in need of any further information regarding radioisotopes or radiopharmaceuticals and our worldwide service, please contact us:
Phone: +49 89 329 8986 6000